Special Issue

Botulinum Toxin Treatment for Pain and Inflammation in Functional Urological Disorders

Message from the Guest Editor

The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity: sensory disorders; bladder pain and pelvic pain; and inflammatory disorders at the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue will cover the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.

Guest Editor

Prof. Dr. Hann-Chorng Kuo

Department of Urology, Hualien Tzu Chi Hospital, Tzu Chi Medical Foundation, Buddhist Tzu Chi University, Hualien, Taiwan

Deadline for manuscript submissions

closed (31 December 2019)



Toxins

an Open Access Journal by MDPI

Impact Factor 4.0
CiteScore 8.2
Indexed in PubMed



mdpi.com/si/26321

Toxins
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
toxins@mdpi.com

mdpi.com/journal/ toxins





Toxins

an Open Access Journal by MDPI

Impact Factor 4.0 CiteScore 8.2 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology, University of Virginia, Charlottesville, VA, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.4 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

